

CONTENTS

DECISIONS

Amendment and supplementation of the Ministerial Decision No 38733/6-5-2014 (Gov. Gazette 1144/B): Amendment of article 14, par. 2 of the Ministerial Decision No οικ.3457 (Gov. Gazette 64/B/16-01-2014): “Regulation of issues for pricing of medicinal products”.

Amendment of article 1 of the Ministerial Decision 28822/8-4-2014 (Gov. Gazette 878/B): “Revision and supplementation of the lists for the treatment of the severe diseases set out in par. 2 of article 12 of L. 3816/2010 (A6)”.

DECISIONS

No 43063

Amendment and supplementation of the Ministerial Decision No 38733/6-5-2014 (Gov. Gazette 1144/B): Amendment of article 14, par. 2 of the Ministerial Decision No οικ.3457 (Gov. Gazette 64/B/16-01-2014): “Regulation of issues concerning the pricing of medicinal products”.

THE MINISTER OF HEALTH

Having considered:

1. The provisions of article 14, par. 3 of Law 3840/2010 (Gov. Gazette A 53).
2. The provisions of article 90 of the P.D. 63/2005 “Codification of legislation for the Government and Government bodies” (A 98).
3. The P.D. 119/2013 “appointment of the Vice-President of the Government, Ministers, Alternate Ministers and Deputy Ministers” (Gov. Gazette A 153).
4. The provisions of the L.D. 96/1973 and mainly article 17 as amended and in force (Gov. Gazette A 172).
5. The provisions of the L.D. 136/1946 “for the Market Police Code” (Gov. Gazette A’ 298), as amended and in force.
6. The provisions of article 13 of Law 3408/2005, as amended and in force (Gov. Gazette A 272).
7. The provisions of Law 3842/2010 (Gov. Gazette A 58) as amended and in force.
8. The provisions of article 4 par. 2 of Law 3899/2010 (Gov. Gazette A 212), for the amendment of VAT Code.
9. The provisions of article 32 of Law 1316/1983 “Establishment, Organisation and competencies of EOF” (Gov. Gazette A 3), as already amended and in force.
10. The provisions of the P.D. 95/2000 “Organisation of the Ministry of Health and Welfare” (A 76), as amended and in force.
11. The provisions of articles 38, 39, 40 and 51 of Law 3918/2011 (Gov. Gazette A 31) as amended and in force.
12. The provisions of articles 11, 16, 17 19, 20, 21 and 23 of Law 4052/2012 (Gov. Gazette A 41).
13. The Joint Ministerial Decision (KYA) No ΔΥΓ3α/Γ.Π.32221/2013 (Gov. Gazette 1049/B/29.4.2013), “approximation of Greek legislation to the respective European

one in the area of production and marketing of medicinal products for human use, in compliance with the directive 2001/83/EC “on the Community code relating to medicinal products for human use (Law 311/28.11.2001) as in force and as amended by the Directive 2010/84/EU, regarding pharmacovigilance (Law 348/21.12.2010) regarding pharmacovigilance”.

14. The Ministerial Decision No ΔΥΓ3(α)/οικ.86767/10.9.2012 “Revocation of the decision for the application of competencies to EOF regarding the pricing of medicinal products” (Gov. Gazette 2462/B).

15. The Ministerial Decision No ΔΥΓ3(α)/οικ.94274/28.9.2012 “Application of article 15 in Law 4052/2012” (Gov. Gazette 2675/B).

16. The Ministerial Decision No 3457 (Gov. Gazette 64/B/16-01-2014 “Regulation of issues concerning the pricing of medicinal products”.

17. The Ministerial Decision No 325/5851/Γ.Π. (Gov. Gazette 88/B/21-01-2014) on “Provisions for Pricing of Medicinal Products”.

18. The provisions of the Ministerial Decision No 22405 (Gov. Gazette 740B/26-03-2014) “Approval of the positive list set out in article 12 par. 1 clause a of Law 3816/2010, as amended and currently in force”.

19. The provisions of article 12 of law 3816/2010 (Gov. Gazette A/26-01-2010), as supplemented by par. 5 of article 63 of Law 3918/2011 (A 31) and the provisions of article 51 of law 3918/2011 (A 31).

20. The Ministerial Decision No Γ.Υ./ΟΙΚ 6161 (Gov. Gazette 2761/B/30-10-2013).

21. The Ministerial Decision No ΔΥΓ3(α)/οιλ.104744, as amended by the Ministerial Decision No ΔΥΓ3(α)/οικ.19389 (Gov. Gazette 3356/B/17-12-2012) according to the Ministerial Decision No 82961 9Gov. Gazette 2219/B/09-09-2013).

22. The provisions of article 22 of Law 4213/2013 (Gov. Gazette 261/A7/9-12-2013).

23. Article 34 of Law 4025/2011 (Gov. Gazette 228/A/2-11-2011).

24. Article 127, par. 6 of Law 4249/2014 (Gov. Gazette 73/A/24-03-2014).

25. The Ministerial Decision No οικ. 38733/6-5-2014 (Gov. Gazette 1144/B).

26. The Order No οικ.2927/15-05-2014 of the Minister of Health.

We decide:

A last clause is added to the Ministerial Decision No 38733/6-5-2014 (Gov. Gazette 1144/B)as follows:

“The amount covered by the patient apart from the enacted participation cannot exceed the amount of Euro fifty (€50) per single medicinal product”.

This decision must be published in the Government Gazette.

Athens, May 16, 2014

THE MINISTER

SPYRIDON-ADONIS GEORGIADIS

No. οικ.43065

Amendment of article 1 of the Ministerial Decision 28822/8-4-2014 (Gov. Gazette 878/B): “Revision and supplementation of the lists for the treatment of the severe diseases set out in par. 2 of article 12 of L. 3816/2010 (A6)”.

THE MINISTER OF HEALTH

Having considered:

1. The provisions of par. 2 of article 12 of Law 3816/2010 (A6) as amended and in force.
2. The provisions of article 23 of Law 4052/2012 (Gov. Gazette A 41).
3. The provisions of article 30 of Law 4058/2012 (A63).
4. The provisions of the P.D. 95/2000 “Organisation of the Ministry of Health and Welfare” (A 76), as amended and in force.
5. The provisions of article 90 of the P.D. 63/2005 “Codification of legislation for the Government and Government bodies” (A 98).
6. The provisions of the P.D. 119/2013 “appointment of the Vice-President of the Government, Ministers, Alternate Ministers and Deputy Ministers” (Gov. Gazette A 153/A/25-6-2013).
7. The Ministerial Decision No ΔΥΓ3(α)/οικ.ΓΥ147 (Gov. Gazette 543/B/01-03-2012) as amended by the Ministerial Decisions No ΔΥΓ3(α)/οικ.34092 (Gov. Gazette 1003/B/02-03-2012) and ΔΥΓ3(α)/οικ.13833 (Gov. Gazette 235/B/07-02-2013).
8. The document under protocol number 36809/15-04-2014 of the President of EOF.
9. The document under protocol number 42477/15-05-2014 of the Directorate of Medicinal Products and Pharmacies of the Ministry of Health.
10. The Order under protocol No οικ.2926/05-05-2014 of the Minister of Health.
11. The fact that no expenditure against the State’s budget is incurred from the provisions of this decision, we decide:

Article 1

The lists of medicinal patent medicines of the Ministerial Decision No ΔΥΓ3(α)/οικ.ΓΥ147 (Gov. Gazette ΔΥΓ3(α)/οικ.34092 (Gov. Gazette 1003/B/02-04-2013) as amended by the Ministerial Decisions No ΔΥΓ3(α)/οικ.34092 (Gov. Gazette 1003/B/02-03-2012) and ΔΥΓ3(α)/οικ.13833 (Gov. Gazette 235/B/07-02-2013) are revised as follows:

MEDICINAL PRODUCTS ONLY FOR IN-HOSPITAL USE (PAR. 1-No 11 of the M.D. 3457/16.01.2014)			
S/N	MEDICINAL PRODUCT	ACTIVE SUBSTANCE	THERAPEUTIC CATEGORY
1	ABRAXANE	PACLITAXEL	ANTINEOPLASTIC
2	ACLASTA	ZOLENDRONIC ACID MONOHYDRATE	DIPHOSPHATES
3	ACTILYSE CATHFLO	ALTEPLASE	ANTICOAGULANTS
4	ADCETRIS	BRENTUXIMAB VEDOTIN	ANTINEOPLASTIC
5	ADRIBLASTINA	DOXORUBICIN HYDROCHLORIDE	ANTINEOPLASTIC
6	ALDURAZYME	A-L-IDURONIDASE	ENZYMES
7	ALIMTA	PEMETREXED DISODIUM	ANTINEOPLASTIC
8	ARITAXEL	DOCETAXEL	ANTINEOPLASTIC

9	ARZERRA	OFATUMUMAB	ANTINEOPLASTIC
10	ATRIANCE	NELARABINE	ANTINEOPLASTIC ORPHAN
11	AVASTIN	BEVACIZUMAB	ANTINEOPLASTIC
12	AXOPLAN	OXALIPLATIN	ANTINEOPLASTIC
13	BENLYSTA	BELIMUMAB	ANTINEOPLASTIC
14	BERINERT	C1 ESTERASE INHIBITOR	MEDICINAL PRODUCTS FOR THE TREATMENT OF ACUTE INCIDENTS OF HEREDITARY VASCULAR ANGIOEDEMA
15	BEROMUN	TASONERMIN	IMMUNOSTIMULANTS
16	BIOTAXEL	PACLITAXEL	ANTINEOPLASTIC
17	BIOTECAN	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
18	BONDRONAT IV	IBANDRONIC AXID	DIPHOSPHATES
19	BRINAVESS	VERNAKALANT HYDROCHLORIDE	OTHER ANTI-ARRHYTHMIC
20	BUSILVEX	BUSULPHAN	ALKYLATING AGENTS
21	CAELYX	DOXORUBICIN HYDROCHLORIDE	ANTINEOPLASTIC
22	CAMPTO	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
23	CEDOL	PACLITAXEL	ANTINEOPLASTIC
24	CEREZYME	IMIGLUCERASE	ENZYMES
25	DACOGEN	DECITABINE	ANTINEOPLASTIC
26	DEMOTAXEL	DOCETAXEL	ANTINEOPLASTIC
27	DOCETAXEL ACTAVIS	DOCETAXEL	ANTINEOPLASTIC
28	DOCETAXEL KABI	DOCETAXEL	ANTINEOPLASTIC
29	DOCETAXEL MYLAN	DOCETAXEL	ANTINEOPLASTIC
30	DOCETAXEL/DE MO	DOCETAXEL	ANTINEOPLASTIC
31	DOCETAXEL/EBE WE	DOCETAXEL	ANTINEOPLASTIC
32	DOCETAXEL/HOS PIRA	DOCETAXEL	ANTINEOPLASTIC
33	DOCETAXEL/SPE CIFAR	DOCETAXEL	ANTINEOPLASTIC
34	DOCETAXEL/TEV A	DOCETAXEL	ANTINEOPLASTIC
35	DOTAXEL	DOCETAXEL	ANTINEOPLASTIC

36	DOXIPROL	DOXORUBICIN	ANTINEOPLASTIC
37	DOXORUBICIN HCL/EBEWE	DOXORUBICIN HYDROCHLORIDE	ANTINEOPLASTIC
38	DOXORUBIN	DOXORUBICIN HYDROCHLORIDE	ANTINEOPLASTIC
39	DOXOTIL	DOXORUBICIN HYDROCHLORIDE	ANTINEOPLASTIC
40	ELAPRASE	IDURSULFASE	ENZYMES
41	ELATOFEN	OXALIPLATIN	ANTINEOPLASTIC
42	ELOXATIN	OXALIPLATIN	ANTINEOPLASTIC
43	ETHYOL	AMIFOSTINE TRIHYDRATE	ANTINEOPLASTIC ANTIDOTES
44	EVOLTRA	CLOFARABINE	ANTINEOPLASTIC ORPHAN
45	EYLEA	AFLIBERCEPT	OPHTHALMOLOGIC MEDICINAL PRODUCTS
46	FABRAZYME	AGALSIDASE BETA	ENZYMES
47	FERINJECT	FERRIC CARBOXYMALTOSE	MEDICINAL PRODUCTS FOR ANAEMIA
48	FLEBOGAMMA	HUMAN NORMAL IMMUNOGLOBULIN	IMMUNOGLOBULIN
49	FLUDARA IV	FLUDARABINE PHOSPHATE	ANTINEOPLASTIC
50	FLUDARABIN/EB EWE	FLUDARABINE PHOSPHATE	ANTINEOPLASTIC
51	FLUDARABIN/TE VA	FLUDARABINE PHOSPHATE	ANTINEOPLASTIC
52	FLUDARABIN/SP ECIFAR	FLUDARABINE PHOSPHATE	ANTINEOPLASTIC
53	FOSFARABINE	FLUDARABINE PHOSPHATE	ANTINEOPLASTIC
54	GAMINEX	HUMAN NORMAL IMMUNOGLOBULIN	IMMUNOGLOBULIN
55	GLIADEL	CARMUSTINE	ANTINEOPLASTIC
56	GLIOLAN	5-AMINOLEVULINIC ACID HYDROCHLORIDE	ANTINEOPLASTIC
57	HALAVEN	ERIBULIN MESYLATE	ANTINEOPLASTIC
58	HEPATECT CP	HEPATITIS B IMMUNOGLOBULIN	IMMUNOGLOBULIN
59	HERCEPTIN	TRASTUZUMAB	ANTINEOPLASTIC
60	HYCAMPTIN inj/ inf	TOPOTECAN HÍ DROCLORIDE	ANTINEOPLASTIC
61	IASIBON	IBANDRONIC AXID	DIPHOSPHATES
62	IG VENA	HUMAN NORMAL IMMUNOGLOBULIN	IMMUNOGLOBULIN

63	INTRATECT	HUMAN NORMAL	IMMUNOGLOBULIN
		IMMUNOGLOBULIN	
64	IRICAN	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
65	IRINOSYN	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
66	IRINOTECAN KABI	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
67	IRINOTECAN MEDICALIS	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
68	IRINOTECAN/ HOSPIRA	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
69	IRINOTECAN/GE NERICS	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
70	IRINOTECAN/TE VA	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
71	IRITEC	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
72	JAVLOR	VINFLUNINE DITATRATE	ANTINEOPLASTIC
73	JETREA	OCRIPLASMIN	OPHTHALMOLOGIC MEDICINAL PRODUCTS
74	JEVTANA	CABAZITAXEL	ANTINEOPLASTIC
75	KIOVIG	HUMAN NORMAL IMMUNOGLOBULIN	IMMUNOGLOBULIN
76	LEUSTATIN	CLADRIBINE	ANTINEOPLASTIC
77	LINOXAL	OXALIPLATIN	ANTINEOPLASTIC
78	LUCENTIS	RANIBIZUMAB	OPHTHALMOLOGIC MEDICINAL PRODUCTS
79	MABTHERA	RITUXIMAB	ANTINEOPLASTIC
80	MACUGEN	PEGAPTANIB SODIUM	OPHTHALMOLOGIC MEDICINAL PRODUCTS
81	MEPACT	MIFAMURTIDE	OTHER IMMUNOSTIMULANTS
82	MIZANTRONE	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
83	MUPHORAN	FOTEMUSTINE	ANTINEOPLASTIC
84	MYOCET	DOXORUBICIN HYDROCHLORIDE	ANTINEOPLASTIC
85	MYOZYME	ALGLUCOSIDASE ALFA	ENZYMES
86	NAVELBINE	VINORELBINE DITARTRATE	ANTINEOPLASTIC
87	NEVOTECAM	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
88	NORMOSANG	HEMIN HUMAN	ACUTE LESION OF HEPATIC PORPHYRIA

89	NULOJIX	BELATACEPT	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
90	ORENCIA IV	ABATACEPT	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
91	OVAPAC	PACLITAXEL	ANTINEOPLASTIC
92	OXALIPATIN/DEL TAPHARMA	OXALIPLATIN	ANTINEOPLASTIC
93	OXALIPLATIN/ GENERICIS	OXALIPLATIN	ANTINEOPLASTIC
94	OXALIPLATIN/ HOSPIRA	OXALIPLATIN	ANTINEOPLASTIC
95	OXALIPLATIN/ TEVA	OXALIPLATIN	ANTINEOPLASTIC
96	OXALIPLATIN/K ABI	OXALIPLATIN	ANTINEOPLASTIC
97	OXALIPLATIN/M EDICALIS	OXALIPLATIN	ANTINEOPLASTIC
98	OXALIPLATIN/M EDICUS	OXALIPLATIN	ANTINEOPLASTIC
99	OXALIPLATIN/TH AMA	OXALIPLATIN	ANTINEOPLASTIC
100	OXALIPROL	OXALIPLATIN	ANTINEOPLASTIC
101	OXAVIATIN	OXALIPLATIN	ANTINEOPLASTIC
102	OZURDEX	DEXAMETHASONE	OPHTHALMOLOGIC MEDICINAL PRODUCTS
103	PACLITAXEL/ GENERICIS	PACLITAXEL	ANTINEOPLASTIC
104	PACLITAXEL/ HOSPIRA	PACLITAXEL	ANTINEOPLASTIC
105	PACLITAXEL/ KABI	PACLITAXEL	ANTINEOPLASTIC
106	PACLITOL	PACLITAXEL	ANTINEOPLASTIC
107	PACLIXEL	PACLITAXEL	ANTINEOPLASTIC
108	PATAXEL	PACLITAXEL	ANTINEOPLASTIC
109	PAXENE PACLITAXEL	PACLITAXEL	ANTINEOPLASTIC
110	PAXITAL	PACLITAXEL	ANTINEOPLASTIC
111	PENTAGLOBIN	HUMAN PLASMA PROTEIN/HUMAN IMMUNOGLOBULINS	IMMUNOGLOBULIN
112	PERJETA	PERTUZUMAB	ANTINEOPLASTIC
113	PEYONA	CAFFEINE CITRATE	XANTHINE PRODUCTION
114	PHOTOFRIN	PORFIMER	OTHER ANTINEOPLASTIC
115	PLAXITIN	OXALIPLATIN	ANTINEOPLASTIC
116	POTACTASOL	TOPOTECAN HYDROCHLORIDE	ANTINEOPLASTIC

117	PRIVIGEN	HUMAN NORMAL IMMUNOGLOBULIN	IMMUNOGLOBULIN
118	PROGRAF IV	TACROLIMUS	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
119	RAPILYSIN	RETEPLASE	ANTICOAGULANTS
120	RECTOXAL	OXALIPLATIN	ANTINEOPLASTIC
121	REPLAGAL	AGALCIDASE ALFA	ENZYMES
122	ROACTEMRA	TOCILIZUMAB	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
123	RUBIDOX	DOXORUBICIN HYDROCHLORIDE	ANTINEOPLASTIC
124	SANTACIL	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
125	SAVENE	DEXTRAZOXANE	ANTINEOPLASTIC ANTIDOTE
126	TAXOL	PACLITAXEL	ANTINEOPLASTIC
127	TAXOPROL	PACLITAXEL	ANTINEOPLASTIC
128	TAXOTERE	DOCETAXEL	ANTINEOPLASTIC
129	TEMODAL PD.SOL.INF	TEMOZOLOMIDE	ANTINEOPLASTIC
130	TOPOCAN	TOPOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
131	TOPOTECAN ACTAVIS	TOPOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
132	TOPOTECAN HOSPIRA	TOPOTECAN HCL	ANTINEOPLASTIC
133	TOPOTECAN KABI	TOPOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
134	TOPOTECAN/TEVA	TOPOTECAN HCL	ANTINEOPLASTIC
135	TOPOVIN	TOPOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
136	TORISEL	TEMSIROLIMUS	ANTINEOPLASTIC
137	TRISENOX	ARSENIC TRIOXIDE	OTHER ANTINEOPLASTIC
138	TYSABRI	NATALIZUMAB	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
139	VECTIBIX	PANITUMUMAB	ANTINEOPLASTIC
140	VELCADE	BORTEZOMIB	ANTINEOPLASTIC
141	VELMINOX	OXALIPLATIN	ANTINEOPLASTIC
142	VENBIG	HEPATITIS B IMMUNOGLOBULIN	IMMUNOGLOBULIN
143	VINORELBIN/EBEWE	VINORELBINE DITARTRATE	ANTINEOPLASTIC

144	VINORELBIN/ME DICALIS	VINORELBINE DITARTRATE	ANTINEOPLASTIC
145	VINTECAN	IRINOTECAN HYDROCHLORIDE	ANTINEOPLASTIC
146	VISUDYNE	VERTEPORFIN	OPHTHALMOLOGIC MEDICINAL PRODUCTS
147	VORELBIN	VINORELBINEDITAR TRATE	ANTINEOPLASTIC
148	VPRIV	VELAGLUCARASE ALFA	ENZYMES
149	XENIUS	PACLITAXEL	ANTINEOPLASTIC
150	YERVOY	IPILIMUMAB	ANTINEOPLASTIC
151	YONDELIS	TRABECTEDIN	ANTINEOPLASTIC
152	ZAKOTAX	DOCETAXEL	ANTINEOPLASTIC
153	ZALTRAP	AFLIBERCEPT	ANTINEOPLASTIC
154	ZAOLIN	VINORELBINE DITARTRATE	ANTINEOPLASTIC
155	ZINFORO	CEFTAROLINE FOSAMIL	ANTIBIOTICS
156	ZOLEDRONIC ACID HOSPIRA	ZOLENDRONIC ACID	DIPHOSPHATES
157	ZOLEDRONIC ACID MYLAN	ZOLENDRONIC ACID	DIPHOSPHATES
158	ZOLEDRONIC ACID TEVA	ZOLENDRONIC ACID	DIPHOSPHATES
159	ZOLEDRONIC ACID TEVA PHARMA	ZOLENDRONIC ACID	DIPHOSPHATES
160	ZOLMESTAT	ZOLEDRONIC ACID MONOHYDRATE	DIPHOSPHATES
161	ZOMETA	ZOLENDRONIC ACID	DIPHOSPHATES
MEDICINAL PRODUCTS WHOSE USE MAY START IN HOSPITALS AND CONTINUE OUTSIDE OF THEM (PAR. 2-No 11 of the M.D. 3457/16.01.2014)			
S/N	MEDICINAL PRODUCT	ACTIVE SUBSTANCE	THERAPEUTIC CATEGORY
162	ABSEAMED	EPOETIN ALFA	ERYTHROPOIESIS STIMULATING AGENTS
163	ADCIRCA	TADALAFIL	MEDICINAL PRODUCTS FOR PULMONARY HYPERTENSION
164	ADVAGRAF	TACROLIMUS	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
165	AFINITOR	EVEROLIMUS	ANTINEOPLASTIC ORPHAN
166	ARANESP	DARBEPOETIN ALFA	ERYTHROPOIESIS STIMULATING AGENTS

167	AVONEX	INTERFERON BETA-1A	IMMUNOREGULATORY PRODUCTS
168	BARACLUDE	ENTECAVIR	SYSTEMATICALLY ADMINISTERED ANTIVIRALS
169	BETAFERON	INTERFERON BETA-1A, RECOMBINANT	IMMUNOREGULATORY PRODUCTS
170	BINOCRIT	EPOETIN ALFA	ERYTHROPOIESIS STIMULATING AGENTS
171	BONDRONAT FC TAB	IBANDRONIC AXID	DIPHOSPHATES
172	BOSULIF	BOSUTINIB	ANTINEOPLASTIC
173	BRAMITOB	TOBRAMYCIN	ANTIMICROBIAL
174	CAPECITABINE TEVA	CAPECITABINE	ANTINEOPLASTIC
175	CARBAGLU	CARGLUMIC ACID	AMINOACIDS AND DERIVATIVES
176	CAYSTON	AZTREONAM	ANTIMICROBIAL ORPHAN
177	CEHADO	ALITRETINOIN	DERMATOLOGICAL PRODUCTS
178	CIMZIA	CERTOLIZUMAB PEGOL	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
179	COPAXONE	GLATIRAMER ACETATE	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
180	COPEGUS	RIBAVIRIN	SYSTEMATICALLY ADMINISTERED ANTIVIRALS
181	DIFICLIR	FIDAXOMICIN	ANTI-INFLAMMATORY/ ANTIDIARRHEAL INTESTINAL MEDICINAL PRODUCTS
182	DUODOPA	CARAÍDOPA+LEVODOPA	AGAINST PARKINSON'S DISEASE ORPHAN
183	ENBREL	ETANERCEPT	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
184	EPORATIO	EPOETIN THETA	ERYTHROPOIESIS STIMULATING AGENTS
185	EPREX	EPOETIN ALFA	ERYTHROPOIESIS STIMULATING AGENTS
186	ESBRIET	PIRFENIDONE	MEDICINAL PRODUCTS FOR IDIOPATHIC PULMONARY FIBROSIS
187	EXJADE	DEFERASIROX	IRON CHELATION THERAPY AGENTS
188	EXTAVIA	INTERFERON BETA-1A, RECOMBINANT	IMMUNOREGULATORY PRODUCTS
189	FAMPYRA	FAMPRIDINE	NEUROLOGICAL MEDICINAL PRODUCTS

190	FERRIPROX	DEFERIPRONE	CHELATE AGENT USED FOR IRON CHELATION THERAPY
191	FIRAZYR	ICATIBANT	MEDICINAL PRODUCTS FOR THE TREATMENT OF ACUTE INCIDENTS OF HEREDITARY VASCULAR ANGIOEDEMA ORPHAN
192	FLUDARA TABS	FLUDARABINE PHOSPHATE	ANTINEOPLASTIC
193	GILENYA	FINGOLIMOD	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
194	GLIVEC	IMATINIB ÂSILATE	ANTINEOPLASTIC
195	GRANOCYTE	LENOGRASTIM	MEDICINAL PRODUCTS FOR NEUTROPENIA
196	GRANULOKINE	FILGRASTIM	MEDICINAL PRODUCTS FOR NEUTROPENIA
197	HEPSERA	ADEFOVIR DIPIVOXIL	SYSTEMATICALLY ADMINISTERED ANTIVIRALS
198	HIZENTRA	HUMAN NORMAL IMMUNOGLOBULIN	IMMUNOGLOBULIN
199	HUMIRA	ADALIMUMAB	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
200	HYCAMTIN CAPS	TOPOTECAN H DROCLORIDE	ANTINEOPLASTIC
201	ILARIS	CANAKINUMAB	IMMUNOSUPPRESSANT ORPHAN
202	INCIVO	TELAPREVIR	SYSTEMATICALLY ADMINISTERED ANTIVIRALS
203	INLYTA	AXITINIB	ANTINEOPLASTIC
204	IRESSA	GEFITINIB	ANTINEOPLASTIC
205	JAKAVI	RUXOLITINIB	ANTINEOPLASTIC
206	KEPIVANCE	PALIFERMIN	AGENTS FOR REDUCING TOXICITY OF CYTOSTATIC THERAPY
207	KINERET	ANAKINRA	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
208	KUVAN	SAPROPTERIN DIHYDROCHLORIDE	METABOLIC DISEASES ORPHAN
209	LONQUEX	LIPEGFILGRASTIM	MEDICINAL PRODUCTS FOR NEUTROPENIA

210	MIRCERA	METHOXY POLYETHYLENE GLYCOL EPOETIN	ERYTHROPOIESIS STIMULATING AGENTS
		BETA	
211	MOZOBIL	PLERIXAFOR	IMMUNOREGULATORY PRODUCTS
212	NAVELBINE CAPS	VINORELBINE DITARTRATE	ANTINEOPLASTIC
213	NEORECORMON	EPOETIN BETA	ERYTHROPOIESIS STIMULATING AGENTS
214	NEULASTA	PEGFILGRASTIM	MEDICINAL PRODUCTS FOR NEUTROPENIA
215	NEXAVAR	SORAFENIB	ANTINEOPLASTIC
216	NIVESTIM	FILGRASTIM	MEDICINAL PRODUCTS FOR NEUTROPENIA
217	NPLATE	ROMIPLOSTIN	ANTI-HAEMORRHAGIC MEDICINAL PRODUCTS
218	ORENCIA sc	ABATACEPT	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
219	PANRETIN	ALITRETINOINE	ANTINEOPLASTIC
220	PEGASYS	PEGINTERFERON ALFA-2A	IMMUNOREGULATORY PRODUCTS
221	PEGINTRON	PEGINTERFERON ALFA-2A	IMMUNOREGULATORY PRODUCTS
222	PROGRAF	TACROLIMUS	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
223	REBETOL	RIBAVIRIN	SYSTEMATICALLY ADMINISTERED ANTIVIRALS
224	REBIF	INTERFERON BETA- 1A	IMMUNOSTIMULANT MEDICINAL PRODUCTS
225	REMICADE	INFLIXIMAB	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
226	REMODULIN	TREPROSTINIL SODIUM	MEDICINAL PRODUCTS FOR PULMONARY HYPERTENSION
227	RETACRIT	EPOETIN ZETA	ERYTHROPOIESIS STIMULATING AGENTS
228	REVATIO	SILDENAFIL	MEDICINAL PRODUCTS FOR PULMONARY HYPERTENSION
229	REVLIMID	LENOLAMIDE	ANTINEOPLASTIC
230	REVOLADE	ELTROMBOPAG	OTHER SYSTEMATIC HAEMOSTATS
231	RIBATREL	RIBAVIRIN	SYSTEMATICALLY ADMINISTERED ANTIVIRALS

232	RIBAVIRIN/SAND OZ	RIBAVIRIN	SYSTEMATICALLY ADMINISTERED ANTIVIRALS
233	RIDOCA	TEMOZOLAMIDE	ANTINEOPLASTIC
234	RILUTEK	RILUZOLE	CNS MEDICINAL PRODUCTS
235	RILUZOLE/ MYLAN	RILUZOLE	CNS MEDICINAL PRODUCTS
236	RIXOR	RIBAVIRIN	SYSTEMATICALLY ADMINISTERED ANTIVIRALS
237	SANDOSTATIN LAR	OCTREOTIDE ACETATE	GROWTH HORMONE COMPETITORS
238	SIGNIFOR	PASIREOTIDE	HYPOTHALAMUS HORMONES
239	SIKLOS	HYDROXYCARBAMI DE	ANTINEOPLASTIC
240	SIMPONI	GOLIMUMAB	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
241	SIMULECT	BASILIXIMAB	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
242	SOMATULINE	LANREOTIDE	GROWTH HORMONE COMPETITORS
243	SOMATULINE AUTO GEL	LANREOTIDE	GROWTH HORMONE COMPETITORS
244	SOMAVERT	PEGVISOMANT	GROWTH HORMONE COMPETITORS
245	SPRYCEL	DASATINIB	ANTINEOPLASTIC
246	STELARA	USTEKINUMAB	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
247	SUTENT	SUNITINIB MALATE	ANTINEOPLASTIC
248	SYNAGIS	PALIVIZUMAB	SPECIAL IMMUNOGLOBULINS FOR A DISEASE RESULTING FROM RSV
249	TACNI	TACROLIMUS	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
250	TARCEVA	ERLOTINIB	ANTINEOPLASTIC
251	TARGRETIN	BEXAROTENE	ANTINEOPLASTIC
252	TASIGNA	NILOTINIB	ANTINEOPLASTIC
253	TEMODAL	TEMOZOLOMIDE	ANTINEOPLASTIC
254	TEMOMEDAC	TEMOZOLOMIDE	ANTINEOPLASTIC
255	TEMOZOLOMIDE / TEVA	TEMOZOLOMIDE	ANTINEOPLASTIC

256	ÿ ÆVAGRASTIM	FILGRASTIM	MEDICINAL PRODUCTS FOR NEUTROPENIA
257	TEYSUNO	TEGAFUR/GIMERACIL/OTERACIL	ANTINEOPLASTIC
258	THALIDOMIDE/C ELGENE	THALIDOMIDE	ANTINEOPLASTIC
259	TOBI	TOBRAMYCIN	ANTIMICROBIAL
260	ÿ ë Åó PODHALER	TOBRAMYCIN	ANTIMICROBIAL
261	TRACLEER	BOSENTAN	MEDICINAL PRODUCTS FOR PULMONARY HYPERTENSION
262	TYVERB	LAPATINIB DITOSYLATE MONOHYDRATE	ANTINEOPLASTIC
263	VENTAVIS	ILOPROST	ANTICOAGULANTS
264	VICTRELIS	BOCEPREVIR	SYSTEMATICALLY ADMINISTERED ANTIVIRALS
265	VIDAZA	AZACITIDINE	ANTINEOPLASTIC
266	VIREAD ñ ^ e Æë Êî î :3 e Ĥŋ ÛŦ I \$ Δ IJf IJŦ ũ (245 mg/ tab)	TENOFOVIR DISOPRIXIL FUMARATE	SYSTEMATICALLY ADMINISTERED ANTIVIRALS
267	VOLIBRIS	AMBRISERTAN	MEDICINAL PRODUCTS FOR PULMONARY HYPERTENSION
268	VOTRIENT	PAZOPANIB	ANTINEOPLASTIC
269	VOTUBIA	EVEROLIMUS	ANTINEOPLASTIC ORPHAN
270	VYNDAQUEL	TAFAMIDIS	NEUROLOGICAL MEDICINAL PRODUCTS
271	XALKORI	CRIZOTINIB	ANTINEOPLASTIC
272	XELODA	CAPECITABINE	ANTINEOPLASTIC
273	XGEVA	DENOSUMAB	OTHER MEDICINAL PRODUCTS ACTIVE IN THE METABOLISM OF THE BONES
274	XOLAIR	OMALIZUMAB	MEDICINAL PRODUCTS ADMINISTERED IN OBSTRUCTIVE LUNG DISEASE
275	ZARZIO	FILGRASTIM	MEDICINAL PRODUCTS FOR NEUTROPENIA
276	ZAVESCA	MIGLUSTAT	METABOLIC DISEASES
277	ZELBORAF	VEMURAFENIB	ANTINEOPLASTIC

278	ZYTIGA	ABIRATERONE ACETATE	ANTINEOPLASTIC
MEDICINAL PRODUCTS THAT WILL CONTINUE TO BE OFFERED BY EOPYY AND PRIVATE PHARMACIES			
279	CELLCEPT	MYCOFENOLATE ACID	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
280	CERTICAN	EVEROLIMUS	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
281	FORSTEO	TERIPARATIDE	MEDICINAL PRODUCTS ACTIVE IN THE METABOLISM OF BONES
282	GENEFADRONE	MITOXANTRONE HÍ DROCLORIDE	ANTINEOPLASTIC
283	IMMUFETE	MYCOFENOLATE MOFETIL	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
284	LYSODREN	MITOTANE	ANTINEOPLASTIC
285	MITOXAN	MITOXANTRONE	ANTINEOPLASTIC
286	MITOXANDRONE /EBEWE	MITOXANTRONE HÍ DROCLORIDE	ANTINEOPLASTIC
287	MYCLAUSEN	MYCOFENOLATE MOFETIL	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
288	MYCOFEN/NEXU S	MYCOFENOLATE MOFETIL	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
289	MYCOFENOLATE MOFETIL/ACTAV IS	MYCOFENOLATE MOFETIL	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
290	MYCOPHENOLAT E MOFETIL/SANDO Z	MYCOFENOLATE MOFETIL	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
291	MYCOPHENOLAT E MOFETIL/GENERI CS	MYCOFENOLATE MOFETIL	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
292	MYFENAX	MYCOFENOLATE MOFETIL	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
293	MYFETIL	MYCOFENOLATE MOFETIL	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
294	MYFORTIC	MYCOPHENOLATE ACID	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
295	NOVANTRONE	MITOXANTRONE	ANTINEOPLASTIC
296	PREOTACT	PARATÓI ROID HORMONE	MEDICINAL PRODUCTS ACTIVE IN THE METABOLISM OF BONES
297	PULMOZYME	DORNASE ALFA	MUCOLYTIC

298	RAPAMUNE	SIROLIMUS	IMMUNOSUPPRESSANT MEDICINAL PRODUCTS
299	RENVELA	SEVELAMER	MEDICINAL PRODUCTS FOR HYPERPHOSPHATEMIA
300	SEBIVO	TELBIVUDINE	SYSTEMATICALLY ADMINISTERED ANTIVIRALS
301	XAGRID	ANAGRELIDE	PLATELET FORMATION INHIBITORS

As for the rest, the Ministerial Decision No ΔΥΓ3(α)/οικ. ΓΥ147 (Gov. Gazette 543/B/01-03-2012), as amended by the Ministerial Decisions No ΔΥΓ3(α)/οικ.34092 (Gov. Gazette 1003/B/02-03-2012) and ΔΥΓ3(α)/οικ.13833 (Gov. Gazette 235/B/07-02-2013).

This Decision must be published in the Government Gazette.

Athens, May 16, 2014

THE MINISTER
SPYRIDON-ADONIS GEORGIADIS